Drugs / E. Coli-Derived Recombinant Protective Antigen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00057525 | Apr 2003 → Apr 2004 | anthrax infection | DynPort Vaccine Company LLC, A GDIT Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E. Coli-Derived Recombinant Protective Antigen | “A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in...” NCT00057525 ↗ |
| Known as | rPA | “In this report we describe a phase I clinical trial testing the safety and immunogenicity of an anthrax vaccine using recombinant Escherichia coli-derived, B. anthracis...” PMID 21079762 ↗ Nov 2010 |